T-SPOT.TB Test: Principles, Procedure, and Interpretation

The T-SPOT.TB test is an interferon-gamma release assay (IGRA) that measures T-cell immune responses to specific Mycobacterium tuberculosis antigens. This article explains how the test works, how samples are processed, and how clinicians interpret results for latent tuberculosis infection (LTBI) and tuberculosis disease. The content is intended for students, researchers, life-science professionals, and informed general readers who need a practical understanding of the test's strengths, limitations, and appropriate clinical use.

At a Glance

The T-SPOT.TB test detects cell-mediated immune memory to M. tuberculosis by counting T cells that release interferon-gamma after exposure to ESAT-6 and CFP-10 antigens. Unlike the tuberculin skin test (TST), the T-SPOT.TB test requires one patient visit for blood collection and does not cross-react with BCG vaccination in most cases.

The test is one of two commercially available IGRA formats, the other being whole-blood ELISA-based assays. Both approaches detect interferon-gamma release but differ in readout, laboratory workflow, and interpretation criteria.

Core Principles of the T-SPOT.TB Assay

The T-SPOT.TB test relies on the principle that T cells from individuals previously exposed to M. tuberculosis produce interferon-gamma when re-encountering specific mycobacterial antigens. The assay uses ESAT-6 and CFP-10, two proteins encoded in the region of difference 1 (RD1) of the M. tuberculosis genome. These antigens are largely absent from BCG vaccine strains and from most nontuberculous mycobacteria, which gives the test improved specificity in BCG-vaccinated populations.

Peripheral blood mononuclear cells (PBMCs) are separated from whole blood, washed, and counted. A standardized number of viable cells is placed into wells pre-coated with antibodies that capture interferon-gamma. The cells are incubated overnight with the antigen panels, along with a positive control (phytohemagglutinin) and a negative control (nil well). After incubation, the plate is developed so that each interferon-gamma-secreting T cell appears as a distinct spot. The spots are counted manually with a microscope or automatically with an ELISPOT plate imager.

The spot count in each antigen well is compared to the nil control. The result is reported as positive, negative, or borderline based on the number of spots above background. The test measures immune response, not the presence of viable bacteria, so it cannot distinguish latent infection from active disease. A positive result indicates infection has occurred at some point, while a negative result indicates no detectable T-cell response to the antigens.

Laboratory Procedure and Workflow

Blood Collection and Transport

The T-SPOT.TB test requires 6 to 8 mL of whole blood collected in sodium heparin tubes. Blood must be processed within a defined window, typically within 8 hours of collection, to maintain cell viability. Samples should be kept at room temperature and never refrigerated or frozen, as temperature extremes reduce PBMC recovery and can produce false-negative results.

Laboratories receiving samples from remote sites must coordinate courier pickup and processing schedules. Delays beyond the recommended processing window should be documented, and the laboratory should note whether the sample was received within acceptable limits. Clinicians should confirm the laboratory's specific transport requirements before ordering the test.

Cell Separation and Counting

The laboratory separates PBMCs using density gradient centrifugation. The buffy coat layer containing mononuclear cells is harvested, washed, and resuspended in culture medium. Cell viability and count are determined using trypan blue exclusion or an automated cell counter. The assay requires a minimum number of viable cells per well, typically 250,000 cells per well. Samples with low viability or insufficient cell numbers may produce indeterminate results.

Incubation and Development

The cell suspension is added to four wells: nil control, ESAT-6 panel, CFP-10 panel, and positive control. The plate is incubated overnight at 37 degrees Celsius with 5% carbon dioxide. After incubation, the plate is washed to remove cells and unbound interferon-gamma. A detection antibody conjugated to an enzyme is added, followed by a substrate that produces an insoluble precipitate at sites where interferon-gamma was captured. Each spot represents one interferon-gamma-secreting T cell.

Spot Counting and Result Reporting

Spots are counted using an ELISPOT reader or manually with an inverted microscope. The number of spots in the nil control is subtracted from the antigen wells to obtain the net spot count. Results are interpreted according to the manufacturer's criteria:

• Positive: net spot count of 8 or more in either antigen panel
• Borderline: net spot count of 5 to 7 in either antigen panel
• Negative: net spot count of 4 or fewer in both antigen panels

The positive control well must show an adequate response for the test to be valid. A failed positive control indicates anergy or technical failure and results in an indeterminate report.

Interpretation of Results

Positive Results

A positive T-SPOT.TB result indicates that the individual has a T-cell memory response to M. tuberculosis antigens. This finding supports a diagnosis of LTBI in asymptomatic individuals or contributes to the diagnostic evaluation of active tuberculosis disease. The test cannot distinguish between latent infection and active disease, so clinical correlation with symptoms, chest imaging, and microbiologic testing is required.

Quantitative spot counts may carry additional clinical information. A retrospective cohort study of more than 8,500 individuals tested at Aarhus University Hospital found that the risk of developing tuberculosis disease increased with higher spot counts, with risk plateauing for tests showing more than ten spots. Compared with negative tests, borderline results carried an adjusted hazard ratio of 5.0 for incident tuberculosis disease, and positive results carried an adjusted hazard ratio of 8.0. For prevalent disease, the adjusted risk ratios were 14.9 for borderline and 35.6 for positive results. These findings suggest that higher spot counts warrant closer clinical attention, although the study authors note that the test's sensitivity for incident disease was 54.0% and for prevalent disease was 78.4%.

Borderline Results

Borderline results, defined as 5 to 7 net spots, present a clinical challenge. The Aarhus cohort study found that borderline results carried substantial risk for both incident and prevalent tuberculosis disease, with adjusted hazard ratios of 5.0 and adjusted risk ratios of 14.9 respectively. These figures indicate that borderline results are not equivalent to negative results and should prompt careful clinical evaluation.

A study comparing manual microscope reading with ELISPOT plate imager reading found that borderline results and positive results with a maximum net spot count of 8 showed relatively high discordance between the two reading methods. The authors recommended manual confirmation of borderline results and positive results with spot counts near the threshold to improve diagnostic accuracy. Laboratories using automated readers should have protocols for manual verification of near-threshold results.

Negative Results

A negative T-SPOT.TB result indicates no detectable T-cell response to ESAT-6 and CFP-10. In immunocompetent individuals, a negative result makes LTBI unlikely. However, false-negative results can occur in severely immunocompromised patients, in very young children, and in individuals with recent exposure before T-cell responses have developed. The test should be repeated or supplemented with other diagnostic information when clinical suspicion remains high.

Indeterminate Results

Indeterminate results occur when the positive control fails to produce an adequate response or when the nil control shows excessive background spots. A failed positive control suggests the individual's T cells are not responding to stimulation, which can happen in severe immunosuppression or when the sample was mishandled. High background in the nil control can result from technical issues or from nonspecific T-cell activation. Indeterminate results do not provide diagnostic information, and the test should be repeated or an alternative diagnostic approach considered.

Diagnostic Accuracy in Specific Populations

Patients with Rheumatic Immune Diseases

Patients with rheumatic immune diseases are considered a high-risk population for developing active tuberculosis. A prospective study of 300 rheumatic disease patients with suspected tuberculosis symptoms compared the diagnostic accuracy of T-SPOT.TB and TST. Among the enrolled patients, 35 (11.7%) were diagnosed with active tuberculosis. The study found that patients with active tuberculosis had significantly higher frequencies of night sweats compared to those without active disease. The study authors note that diagnostic accuracy in this population remains underexplored because immune dysfunction can affect test performance.

Children and Adolescents with Juvenile Idiopathic Arthritis

A prospective longitudinal study of children and adolescents with juvenile idiopathic arthritis undergoing methotrexate therapy evaluated TST and T-SPOT.TB for LTBI diagnosis. Among 24 patients, the prevalence of LTBI at inclusion was 20.8%, rising to 41.6% by the end of the study. The T-SPOT.TB test showed a sensitivity of 10% and specificity of 92.8% in this small cohort, with low correlation with TST results. The authors found no superiority of T-SPOT.TB over TST in this population and noted low agreement between the two tests. The study's small sample size limits the generalizability of these findings, but the results highlight that IGRA performance in immunosuppressed pediatric populations may differ from adult populations.

Healthcare Workers

Healthcare workers face elevated risk of tuberculosis exposure, and screening programs rely on accurate tests for LTBI detection. A longitudinal multicenter comparative study examined IGRA versus TST for tuberculosis screening in exposed healthcare workers. The study compared the performance of these tests in serial screening programs, providing evidence for the practical use of IGRA in occupational health settings.

A separate retrospective cohort study of healthcare workers in a tertiary hospital examined tuberculosis exposure frequency and LTBI incidence by occupational classification. Among 2,116 healthcare workers, exposure rates increased with higher risk classification, ranging from 46.9% in the highest-risk group to 0.6% in the lowest-risk group. The incidence of LTBI was 1.0% over one year. After adjustment, LTBI incidence was associated with two or more tuberculosis exposure events, with an adjusted odds ratio of 7.03, but did not differ significantly by occupational group classification. This finding suggests that the number of exposure events, instead of job category alone, drives infection risk.

Patients with Ocular Tuberculosis

A nested case-control study evaluated T-SPOT.TB performance in patients with ocular tuberculosis in a BCG-vaccinated, non-endemic population. The study enrolled 23 patients with ocular tuberculosis and 22 patients with other causes of uveitis. Laboratory professionals were blinded to disease status. The calculated sensitivity was 0.80 and specificity was 0.85, with a positive likelihood ratio of 5.33 and negative likelihood ratio of 0.23. The overall accuracy was 0.83. The authors concluded that T-SPOT.TB adequately diagnosed ocular tuberculosis and is particularly useful in populations where BCG vaccination is mandatory.

Tuberculous Pleurisy

A systematic review and meta-analysis evaluated the diagnostic value of T-SPOT.TB and adenosine deaminase (ADA) in pleural effusion for tuberculous pleurisy. The analysis included 10 studies with 2,075 patients, of whom 1,391 had tuberculous pleurisy and 684 had non-tuberculous pleurisy. The pooled sensitivity of T-SPOT.TB was 0.88 and specificity was 0.79, with a diagnostic odds ratio of 35.72 and area under the summary receiver operating characteristic curve of 0.9283. ADA showed pooled sensitivity of 0.65 and specificity of 0.90. The authors noted substantial heterogeneity across studies, with I-squared values above 90% for most pooled estimates, indicating that individual study results varied considerably.

Tuberculous Meningitis

A retrospective analysis of 96 patients with meningitis evaluated the diagnostic value of cerebrospinal fluid T-SPOT.TB for tuberculous meningitis. The sensitivity, specificity, positive predictive value, and negative predictive value were 97.8%, 78.0%, 80.3%, and 97.5% respectively, for 52 patients with confirmed diagnoses. The area under the receiver operating characteristic curve was 0.910. Sensitivities for patients with stages I, II, and III of tuberculous meningitis were 96.7%, 97.2%, and 98.9% respectively. The authors concluded that cerebrospinal fluid T-SPOT.TB is a rapid and accurate diagnostic method for tuberculous meningitis.

Pulmonary and Extrapulmonary Tuberculosis

A clinical evaluation of T-SPOT.TB in northeastern Guangdong Province, China enrolled 2,868 patients who underwent T-SPOT.TB, sputum smear, and TB-DNA testing simultaneously. The sensitivity of T-SPOT.TB was 61.44%, compared to 37.12% for TB-DNA and 14.02% for sputum smear. Specificity was 76.49% for T-SPOT.TB, lower than the 99.20% for TB-DNA and 99.60% for sputum smear. The T-SPOT.TB positive rate was higher in pulmonary and extrapulmonary tuberculosis subgroups than in patients with other pulmonary diseases, at 61.38% and 61.76% versus 23.34%. The authors found that T-SPOT.TB had moderate sensitivity and specificity for diagnosing tuberculosis, with better diagnostic accuracy when using adjusted cutoff values for the ESAT-6 and CFP-10 markers.

Bone and Joint Tuberculosis

A comparative study examined the value of Xpert MTB/RIF and T-SPOT.TB tests in the diagnosis of bone and joint tuberculosis. The study compared the diagnostic performance of molecular detection of M. tuberculosis DNA with the T-cell-based immune response assay in this extrapulmonary form of tuberculosis. The findings support the use of T-SPOT.TB as part of the diagnostic workup for osteoarticular tuberculosis, where microbiologic confirmation is often difficult.

Intestinal Tuberculosis

A study evaluated the diagnostic value of T-SPOT.TB in intestinal tuberculosis. Intestinal tuberculosis presents diagnostic challenges because its clinical and endoscopic features overlap with Crohn's disease and other inflammatory bowel conditions. The T-SPOT.TB test provides a blood-based immunologic marker that can support the differential diagnosis, although the study's findings should be considered alongside endoscopic biopsy and microbiologic testing.

Urinary Tuberculosis

A 2025 study examined the diagnostic value of combining leukocyte testing in urine with TB-DOT and T-SPOT.TB in blood for urinary tuberculosis. The combined approach aims to improve diagnostic accuracy for this paucibacillary form of extrapulmonary tuberculosis, where conventional smear and culture often yield negative results.

Fever of Unknown Origin

A prospective cohort study of 100 tuberculosis patients and 81 lymphoma patients presenting with fever of unknown origin found that the positive rate of T-SPOT.TB was significantly higher in the tuberculosis group than in the lymphoma group. The study developed a diagnostic prediction model combining clinical parameters that achieved an area under the curve of 0.96 in the derivation cohort and 0.948 in the validation cohort. Muscle pain and chills were more common in tuberculosis patients, while hepatosplenomegaly and lymphadenopathy were more prevalent in lymphoma patients.

Nontuberculous Mycobacterial Pulmonary Disease

A retrospective analysis of patients with nontuberculous mycobacterial pulmonary disease found that the positive rate of T-SPOT.TB was higher in patients without bronchiectasis than in those with bronchiectasis, at 47.37% versus 8.33%. This finding is relevant because nontuberculous mycobacteria can cause false-positive IGRA results in some cases, and the clinical context must be considered when interpreting positive results.

Comparison with Tuberculin Skin Test

The TST has been the standard screening test for LTBI for decades, but it has well-documented limitations. The TST uses purified protein derivative, a mixture of antigens shared with BCG vaccine strains and many nontuberculous mycobacteria. In BCG-vaccinated populations, the TST produces false-positive results that complicate interpretation. The TST also requires two patient visits, and reading requires trained personnel to measure induration accurately at 48 to 72 hours.

The T-SPOT.TB test addresses several of these limitations. The use of ESAT-6 and CFP-10 antigens, which are absent from BCG strains, reduces false-positive results in vaccinated individuals. The test requires a single blood draw and produces objective spot counts that can be verified. However, the test requires laboratory infrastructure, trained personnel, and timely sample processing, which may limit availability in resource-limited settings.

A study comparing T-SPOT.TB and TST in patients with rheumatic immune diseases found that both tests have roles in tuberculosis diagnosis, but their accuracy in immunocompromised populations remains underexplored. A study of contact tracing found that the T-cell-based test showed better correlation with tuberculosis exposure than the TST, supporting its use in contact investigation programs.

Quantitative Results and Risk Stratification

The T-SPOT.TB test produces quantitative spot counts that may carry prognostic information beyond the qualitative positive or negative result. The Aarhus University Hospital cohort study found that the risk of incident tuberculosis disease increased with higher spot counts, plateauing for tests with more than ten spots. This finding suggests that spot counts could inform risk stratification, with higher counts warranting more urgent evaluation and possibly treatment for LTBI.

The same study identified that borderline results, defined as 5 to 7 spots, carried substantial risk for both incident and prevalent tuberculosis disease. Clinicians should not dismiss borderline results as equivocal findings without clinical significance. Instead, borderline results should prompt careful assessment of symptoms, exposure history, and chest imaging, with consideration of repeat testing or treatment based on the overall clinical picture.

The study also found that the strongest risk factors for both incident and prevalent tuberculosis disease were the categorical T-SPOT.TB results themselves, compared with demographic and comorbidity variables. This finding underscores the value of the test as a risk stratification tool, while acknowledging that sensitivity for incident disease was modest at 54.0%.

Automated Reading and Quality Control

ELISPOT plate imagers offer an alternative to manual microscope reading, reducing labor and improving throughput. A study comparing manual reading with automated imaging for 1,423 test results found an overall percent agreement of 95.43% with a kappa coefficient of 0.91. The agreement of spot counts in the antigen panels and nil control was good, and variability did not increase with higher spot counts.

However, the study identified specific situations where automated reading showed relatively high discordance with manual reading. Positive test results with a maximum net spot count of 8 and borderline test results were the most problematic categories. The authors proposed a novel strategy for interpreting automated results: positive results with a maximum net spot count of 8 and borderline results should be manually confirmed to increase diagnostic accuracy. Laboratories using automated readers should implement this verification step as part of their quality control procedures.

Machine Learning Approaches to Interpretation

Recent work has explored machine learning models that combine T-SPOT.TB results with routine clinical data to improve diagnostic accuracy. A study of 486 patients with pleural effusion developed a simplified random forest model using six features that achieved an area under the curve of 0.939, accuracy of 0.887, sensitivity of 0.862, and specificity of 0.923. External validation yielded an area under the curve of 0.917. The model incorporated pleural adenosine deaminase levels along with T-SPOT.TB results and other clinical variables.

These approaches are promising but remain investigational. Clinicians should interpret machine learning outputs as decision support tools instead of definitive diagnostic results. The models require external validation across diverse populations before they can be recommended for routine clinical use.

Practical Workflow for Clinicians

Step 1: Determine Test Appropriateness

The T-SPOT.TB test is appropriate for screening individuals at risk for LTBI, including contacts of active tuberculosis cases, healthcare workers, and immunocompromised patients. The test can also contribute to the diagnostic evaluation of suspected active tuberculosis, particularly in extrapulmonary forms where microbiologic confirmation is difficult. The test is not recommended for serial testing of low-risk individuals, as false-positive conversions can occur.

Step 2: Order the Test and Arrange Logistics

Confirm that the laboratory offers T-SPOT.TB testing and can process samples within the required time frame. Arrange blood collection in sodium heparin tubes and coordinate transport to the laboratory. Document the time of collection and the time of laboratory receipt to verify that processing occurred within the acceptable window.

Step 3: Interpret Results in Clinical Context

Interpret the qualitative result (positive, borderline, negative, or indeterminate) alongside the quantitative spot counts. Consider the patient's immune status, exposure history, symptoms, and chest imaging findings. A positive result in an asymptomatic individual supports LTBI diagnosis and prompts discussion of treatment. A positive result in a symptomatic individual requires evaluation for active tuberculosis, including sputum smear, culture, and molecular testing.

Step 4: Document and Follow Up

Record the test result, spot counts, and clinical interpretation in the patient record. For borderline results, document the plan for repeat testing or clinical monitoring. For indeterminate results, document the likely cause and the plan for alternative testing. Schedule follow-up as indicated by the clinical situation.

Records and Measurements

Laboratories should maintain records of the following for each T-SPOT.TB test:

• Patient identifier and specimen accession number
• Date and time of blood collection
• Date and time of laboratory receipt
• Date and time of sample processing
• PBMC yield and viability
• Spot counts for nil control, ESAT-6 panel, CFP-10 panel, and positive control
• Qualitative result and interpretation
• Reading method (manual or automated)
• Any quality control failures or repeat testing

Clinicians should document the clinical indication for testing, the result, and the action taken based on the result. This documentation supports continuity of care and provides data for programmatic evaluation of screening effectiveness.

Common Failure Patterns and Troubleshooting

False-Negative Results

False-negative T-SPOT.TB results can occur in several situations. Severe immunosuppression, including advanced HIV infection, hematologic malignancy, or high-dose immunosuppressive therapy, can impair T-cell responses. Recent tuberculosis exposure may precede the development of detectable T-cell responses, and testing too soon after exposure can produce false-negative results. Improper sample handling, including delayed processing, temperature extremes, or inadequate cell viability, can also cause false-negative results.

False-Positive Results

False-positive results can occur in individuals infected with nontuberculous mycobacteria that share ESAT-6 or CFP-10 antigens with M. tuberculosis. The study of nontuberculous mycobacterial pulmonary disease found that 47.37% of patients without bronchiectasis had positive T-SPOT.TB results, highlighting the potential for cross-reactivity. Prior tuberculosis infection that has been adequately treated will typically remain positive, so a positive result does not indicate active disease or reinfection.

Indeterminate Results

Indeterminate results require systematic troubleshooting. A failed positive control suggests anergy or technical failure. The laboratory should verify cell viability, reagent integrity, and incubation conditions. If the positive control fails in a patient with known immunosuppression, the result may reflect true anergy instead of technical failure. High background in the nil control can result from platelet contamination, excessive red blood cells, or nonspecific T-cell activation. The laboratory should repeat the test with a fresh sample if possible.

Discordance Between Automated and Manual Reading

Laboratories using ELISPOT plate imagers should verify borderline results and positive results with spot counts near the threshold manually. The study comparing reading methods found that these categories showed the highest discordance. Manual confirmation reduces the risk of misclassification and improves diagnostic accuracy.

Limitations and Considerations

The T-SPOT.TB test cannot distinguish latent infection from active disease. A positive result indicates infection has occurred but provides no information about bacterial burden, disease activity, or risk of progression. Clinicians must integrate the test result with clinical, radiologic, and microbiologic data to make treatment decisions.

The test has variable sensitivity across different forms of tuberculosis. Sensitivity is higher for pulmonary tuberculosis and tuberculous meningitis but lower for some extrapulmonary forms. The meta-analysis of tuberculous pleurisy found pooled sensitivity of 0.88, while the clinical evaluation in Guangdong found sensitivity of 61.44% for all tuberculosis cases. These differences reflect variations in study populations, disease severity, and reference standards.

The test requires laboratory infrastructure that may not be available in all settings. Blood samples must be processed within hours of collection, which limits use in remote or resource-limited areas. The cost of the test is higher than the TST, which may affect availability in public health programs.

The test's performance in immunocompromised populations is variable. The study of children with juvenile idiopathic arthritis found low sensitivity of 10%, while the study of rheumatic disease patients found that diagnostic accuracy in this population remains underexplored. Clinicians should interpret negative results cautiously in severely immunocompromised patients and consider repeat testing or alternative diagnostic approaches.

Regulatory and Safety Context

The T-SPOT.TB test is an in vitro diagnostic device that must be used according to the manufacturer's instructions and applicable regulatory requirements. Laboratories performing the test should participate in external quality assessment programs and follow standard operating procedures for sample handling, processing, and reporting.

Blood collection carries standard phlebotomy risks, including bruising, bleeding, and infection at the venipuncture site. Laboratory personnel handling blood samples must follow universal precautions to prevent exposure to bloodborne pathogens. The test itself poses no risk to patients beyond the blood draw.

Interpretation of tuberculosis tests should follow current clinical guidelines, which may vary by jurisdiction. Clinicians should consult local public health authorities for guidance on LTBI screening, treatment, and reporting requirements. Positive results in healthcare workers may trigger occupational health evaluation and follow-up testing according to institutional policy.

Professional Escalation Criteria

Clinicians should consider referral or consultation in the following situations:

• Indeterminate T-SPOT.TB results in patients with suspected immunosuppression, where anergy testing or alternative diagnostic approaches may be needed
• Positive T-SPOT.TB results in symptomatic patients, where evaluation for active tuberculosis disease is required
• Borderline results in patients with high exposure risk or significant comorbidities, where the risk of progression warrants careful assessment
• Discordant results between T-SPOT.TB and TST, where the clinical picture should guide further evaluation
• Positive results in pregnant women, young children, or other special populations where treatment decisions require specialized expertise
• Suspected false-positive results in patients with nontuberculous mycobacterial disease, where speciation and clinical correlation are needed

Frequently Asked Questions

What is the difference between the T-SPOT.TB test and the tuberculin skin test?

The T-SPOT.TB test measures T-cell interferon-gamma release after exposure to M. tuberculosis-specific antigens, while the TST measures delayed-type hypersensitivity to purified protein derivative. The T-SPOT.TB test requires one blood draw and is not affected by BCG vaccination, while the TST requires two visits and produces false-positive results in BCG-vaccinated individuals.

How long does it take to get T-SPOT.TB test results?

The test requires overnight incubation of cells with antigens, followed by plate development and spot counting. Results are typically available the day after the blood sample is received by the laboratory. The total time from blood collection to result depends on transport logistics and laboratory workflow.

What does a positive T-SPOT.TB test mean?

A positive result indicates that the person's T cells recognize M. tuberculosis antigens and produce interferon-gamma in response. This finding indicates that infection with M. tuberculosis has occurred at some point. The test cannot distinguish between latent infection and active disease, so clinical evaluation is needed to determine the appropriate management.

Can the T-SPOT.TB test distinguish between latent infection and active tuberculosis disease?

No. The test detects an immune response to M. tuberculosis antigens, which is present in both latent infection and active disease. Distinguishing between these conditions requires clinical assessment, chest imaging, and microbiologic testing such as sputum smear, culture, or molecular assays.

What causes an indeterminate T-SPOT.TB result?

An indeterminate result occurs when the positive control fails to show an adequate response or when the nil control shows excessive background spots. A failed positive control can result from severe immunosuppression or technical failure. High background can result from sample handling issues or nonspecific T-cell activation. Indeterminate results do not provide diagnostic information and require repeat testing or alternative approaches.

How accurate is the T-SPOT.TB test for diagnosing tuberculosis?

Accuracy varies by clinical context and population. The test shows higher sensitivity for pulmonary tuberculosis and tuberculous meningitis but lower sensitivity for some extrapulmonary forms. Specificity is generally high, particularly in BCG-vaccinated populations, but false-positive results can occur with nontuberculous mycobacterial infection. Clinicians should interpret results in the context of the individual patient's risk factors and clinical presentation.

Is the T-SPOT.TB test affected by BCG vaccination?

The T-SPOT.TB test uses ESAT-6 and CFP-10 antigens that are absent from BCG vaccine strains, so prior BCG vaccination does not cause a positive result. This is a major advantage over the TST in populations with high BCG coverage.

Can the T-SPOT.TB test be used for serial screening of healthcare workers?

Yes, the test can be used for serial screening, and it avoids the booster phenomenon seen with repeated TST administration. However, serial IGRA testing can produce conversions and reversions that may not reflect true infection status. The study of healthcare workers found that LTBI incidence was associated with multiple exposure events, suggesting that screening programs should focus on workers with documented exposures.

Related Articles

• ELISA Workflow: Designing Controls and Interpreting Plate Results
• Gene Set Enrichment Analysis for RNA-seq: Choosing and Interpreting Results
• Pcr Test
• Pcr Test
• Pcr Test

References and Further Reading

• Research Data Framework. National Institute of Standards and Technology.
• EQUATOR Network. EQUATOR Network.
• Experimental Design Assistant. NC3Rs.
• NCBI Literature Resources. National Center for Biotechnology Information.
• PubMed. National Library of Medicine.
• Diagnostic accuracy of T-SPOT.TB and TST in detecting active tuberculosis in patients with rheumatic immune diseases: a fully matched comparative study.. BMC infectious diseases, 2025.
• Evaluating stratified T-SPOT.TB results for diagnostic accuracy in tuberculosis disease: a retrospective cohort study with sensitivities, specificities, and predictive values.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025.
• The diagnostic value of T cell spot test and adenosine deaminase in pleural effusion for tuberculous pleurisy: A systematic review and meta-analysis.. Tuberculosis (Edinburgh, Scotland), 2022.
• Clinical evaluation of the T-SPOT.TB test for detection of tuberculosis infection in northeastern Guangdong Province, China.. The Journal of international medical research, 2020.
• Evaluation of the Accuracy of T-SPOT.TB for the Diagnosis of Ocular Tuberculosis in a BCG-vaccinated, Non-endemic Population.. Ocular immunology and inflammation, 2017.
• Tuberculin skin test and ELISPOT/T. SPOT.TB in children and adolescents with juvenile idiopathic arthritis.. Pediatric rheumatology online journal, 2014.
• A novel strategy for interpreting the T-SPOT.TB test results read by an ELISPOT plate imager.. PloS one, 2019.
• Diagnostic Value of Cerebrospinal Fluid T-SPOT.TB for Tuberculousis Meningitis in China.. Biomedical and environmental sciences : BES, 2017.
• Development and validation of a simplified machine learning model based on T-SPOT.TB and routine clinical data for the diagnosis of tuberculous pleural effusion.. 2026.
• Comparison of Tuberculosis Exposure Frequency and Latent Tuberculosis Infection Rates Among Healthcare Workers by Occupational Classification.. 2026.
• Detect early TB infection, evaluate contacts for TB (DETEC-TB) - a protocol for a prospective cohort study on active case finding for tuberculosis disease and tuberculosis infection source tracing.. 2025.
• Clinical Characteristics and Risk Factors Analysis of Nontuberculous Mycobacterial Pulmonary Disease Complicated with Bronchiectasis.. 2026.
• Clinical and Laboratory Discriminators for Tuberculosis and Lymphoma in Adults Presenting with Fever of Unknown Origin: A Prospective Cohort Study.. 2026.
• Comparison of QuantiFERON-TB In Tube test and T-SPOT.TB with tuberculin skin test in HIV- infected individuals from an intermediate tuberculosis burden country. 2010.
• Interferon-γ Release Assay vs. Tuberculin Skin Test for Tuberculosis Screening in Exposed Healthcare Workers: A Longitudinal Multicenter Comparative Study. Infection Control &#x0026, Hospital Epidemiology, 2015.
• Diagnostic value of T-SPOT. TB in intestinal tuberculosis. 2014.
• Contact tracing using a new T-cell-based test: better correlation with tuberculosis exposure than the tuberculin skin test.. The International Journal of Tuberculosis and Lung Disease, 2005.
• A comparative study on the value of Xpert MTB/RIF and T-SPOT.TB tests in the diagnosis of bone and joint tuberculosis. Clinica Chimica Acta, 2020.
• Diagnostic value of the combined test of leukocytes in urine and TB-DOT and T-SPOT.TB in blood for urinary tuberculosis. Frontiers in Microbiology, 2025.

This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.